INTRODUCTION
Attempts to target the altered signaling pathways at molecular level have been proven to be effective for the treatment of cancer. Kinases in signal transduction process are closely implicated in tumor cell proliferation and survival, which has led to the development of small kinase inhibitors for cancer intervention. Imatinib, a small-molecule tyrosine kinase inhibitor (TKI) targeting the fusion protein of BCR-ABL kinase found in chronic myeloid leukemia (CML), has been widely used in the CML treatment, exhibiting up to 80% response rate (Druker et al., 1996; Zhang et al., 2009 ).
However, despite this exciting therapeutic efficacy, significant challenges are faced due to drug resistance and side effects of imatinib, resulting in high relapse rate and dose reduction respectively. Although second-generation TKIs such as dasatinib (Hochhaus et al., 2008) and nilotinib (Saglio et al., 2010) have been developed to overcome imatinib resistance and improve the prognosis of CML patients, resistance to these novel inhibitors still arises partly from the emergence of BCR-ABL mutant clones (O'Hare et al., 2011) . Therefore, it has been a challenging theme to over-come this compromised effectiveness of imatinib as a single agent for successful treatment outcome in the clinic.
In addition to its inhibition of BCR-ABL tyrosine kinases in CML, imatinib targets selectively other receptor tyrosine kinases such as stem cell factor receptor (c-Kit) and platelet-derived growth factor (PDGF) receptor, and is currently used for the treatment of gastrointestinal stromal tumor (GIST) harboring c-Kit mutation (Joensuu et al., 2001; De Giorgi & Verweij, 2005) . Several studies demonstrated that Abl kinases are tyrosine phosphorylated and activated in solid tumors and imatinib promotes apoptosis and inhibits growth of various cancer cells including colorectal cancer (CRC) cells (Attoub et al., 2002; Stahtea et al., 2007; Popow-Wozniak et al., 2011; Abdel-Aziz et al., 2015) . Furthermore, recent reports suggested that imatinib suppresses cell proliferation in intestinal adenomas and CRC cell lines via the regulation of Abl-cyclin D1 pathway (Genander et al., 2009; Kundu et al., 2015) .
Metformin, a biguanide derivative, is a widely prescribed and well-tolerated first-line drug for type II diabetes mellitus. Metformin lowers the blood glucose level by inhibiting hepatic gluconeogenesis and increasing glucose uptake in skeletal muscles, which lead to a decline in circulating insulin levels (Shaw et al., 2005) . Several retrospective studies have described that metformin treatment in diabetic patients significantly reduced the risk of cancer incidence and metformin use in CRC patients with diabetes is associated with decreased mortality, suggesting a potential role of metformin as an anticancer agent (Evans et al., 2005; Lee et al., 2011) . In many preclinical studies, metformin suppressed cellular proliferation, caused apoptosis, induced cell cycle arrest, and decreased the incidence and growth of experimental tumors (Isakovic et al., 2007; Ben Sahra et al., 2008; Tomimoto et al., 2008; Alimova et al., 2009 ).
Moreover, combinatory treatment of metformin and other chemotherapeutic drugs showed the synergistic anti-cancer effects in CRC cells Nanglia-Makker et al., 2014) , demonstrating the possibility of decreasing the dose of chemotherapeutic drugs with severe side effects.
The present study was undertaken to investigate whether metformin could be used in conjunction with imatinib to inhibit the growth of HCT15 CRC cells and to delineate its mechanisms of regulation. Herein, we observed synergistic growth inhibition of HCT15 CRC cells with the combination of imatinib and metformin, and described synergistic down-regulation of pERK, cell cycle arrest, and induction of autophagy as the mechanism explaining effects of the combination.
MATERIAL AND METHODS

Reagents and cell culture
Imatinib (also known as Gleevec) and metformin were purchased from Sigma-Aldrich (St. Louis, Mo, USA). 
Cell viability assay
Cell viability was determined by using MTT method as described previously (Park & Lee, 2014 
Western blotting
Western blotting assays were performed as previously described (Song et al., 2011) 
Statistical analysis
Data were expressed in the form of mean±SEM. The statistical analysis was done by using Student's t Test. Differences between means were considered as significant when yielding p<0.05.
RESULTS
Effect of imatinib, metformin and combination on the cell viability in HCT15 cells
To evaluate the response of HCT15 CRC cells to imatinib and metformin, we first treated HCT15 cells with various concentrations of imatinib and metformin for 48 hr, and cell viability was determined by using MTT assay. As shown in Fig. 1A and B, imatinib and metformin inhibited cell viability in a concentration-dependent manner. IC 50 values of imatinib and metformin were 38.2 μM and 2.7 mM, respectively. Next, we analyzed the effect of imatinib in combination with metformin on cell growth by deter-mining the type of interaction between two drugs. Imatinib and metformin were combined in non-constant ratios, in which the fixed dose of metformin (0.25, 0.5 or 1 mM) were co-treated with different concentrations of imatinib (1.25-10 μM). As shown in Fig 1C, anti-proliferative activity of imatinib was augmented in proportion to increasing doses of metformin. The combination index (CI) values ranged from 0.51 to 0.86, indicating synergism according to the method of Chou-Talalay (Chou & Talalay, 1981) ( Table 1 ). The combination also showed that the values of drug reduction index (DRI) were always above 1 at any combination points of two drugs (Table 2) . We next screened the change of pERK protein, one of the key regulator proteins in signal transduction pathway, by Western blot assay.
Metformin and imatinib each induced a remarkable reduction in pERK, and the combination of metformin and imatinib caused almost complete suppression of pERK level (Fig. 1D) .
Imatinib, metformin and combination induce cell cycle arrest
Since imatinib, metform and their combination decreases Combination treatment of metformin and imatinib resulted in similar pattern of cell cycle distribution as treated with imatinib alone. We further monitored the changes of proteins involved in cell cycle regulation using Western blot.
As shown in Fig. 3 , while there is no apparent alteration in cyclin D 1 and A as compared to control, cyclin B1 levels were remarkably reduced by imatinib, metfromin and their combination treatment.
Effect of imatinib, metformin and combination on autophagy induction
Substantial evidence has been accumulating to reveal that most of chemotherapeutic and molecular targeted agents employed in cancer therapy cause the activation of autophagy in cancer cells (Sui et al., 2013) . Therefore, we (Takeuchi et al., 2005) . It has been also suggested that the microtubule-associated protein light chain 3 (LC3) is a novel marker of autophagy activation. Upon autophagy induction the cytosolic full-length form of LC3-1 (16 kDa) is processed to the cleaved autophagosome-bound form of LC3-II (14 kDa) through lipidation to be associated with autophagic vacuoles (Li et al., 2013) . In our study, metformin alone showed a little increased red fluorescent AVOs formation while imatinib and the combination of metformin and imatinib led to the markedly increased red fluorescent AVOs in the cytoplasm compared to control cells (Fig. 4A) . Western blot analysis revealed that metformin did not show the increase of the lipidated LC3-II form, whereas imatinib and the combination treatments showed the increased level of LC3-II form, consistent with the results observed in AO staining (Fig. 4B ).
Inhibition of autophagy enhances the antitumor activity of imatinib, metformin and combination
It has been suggested that many anti-cancer therapeutic agents induce autopahgy, which acts as either prosurvival or prodeath role of cancer cells (Yang et al., 2011 ). Thus we asked how the inhibition of autophagy affects the anti- tumor activity in our treatment regimen. To this end, we employed a lysosmotropic agent chloroquine (CQ), which interferes with the fusion between autophagosomes and lysosome and thus widely used as an autophagy inhibitor (Mizushima et al., 2010) . As shown in Fig. 5 , co-treatment of metforim, imatinib or their combination with CQ resulted in more decreased cell viability compared to that observed in treatment of metformin, imatinib or combination alone.
Metformin augments the inhibitory effect of imatinib on the colony formation in HCT15 cells
To further confirm the synergistic effect of imatinib in
combination with metformin, we tested the long term effect of this drug combination in a 12-day colony formation assay. As shown in Fig. 6 , imatinib or metformin alone at the tested doses partially inhibited the growth of colony formation. However the combination of imatinib and metformin potentiated the inhibitory effect on the formation and growth of colonies as compared with either agent alone.
Thus, these results further support the synergistic anticancer effect of imatinib and metformin combination treatment 
DISCUSSION
The tyrosine kinase inhibitor imatinib has shown a substantial therapeutic activity in patients with chronic myeloid leukemia (CML), a disease resulting from mutated BCR-Abl kinase. Imatinib also inhibits the catalytic activity of PDGF receptor and c-kit receptor kinase. Therefore, imatinib is successfully used for the treatment of GIST with mutated c-kit tyrosine kinase and several studies have suggested that imatinib inhibits cell proliferation and induces apoptosis in CRC cells (Attoub et al., 2002; Stahtea et al., 2007; Popow-Wozniak et al., 2011; Abdel-Aziz et al., 2015) . However, despite high response rate of imatinib in CML and GIST patients, significant drug resistance and side effects have become a challenging theme in the clinic.
As a candidate to overcome these problems in cancer therapeutics, the biguanide metformin prescribed widely for the diabetes treatment with well tolerable side effects has been tested as a single agent or combination treatment with other drugs since metformin shows the antiproliferative and proapoptotic activity in various cancer cells.
In the present study, we evaluated the effects of metformin, imatinib and their combination in HCT15 CRC cell line, and showed dose-and time-dependent growth inhibitory effect of imatinib and metformin. In addition, the combination resulted in synergistic growth inhibitory effects in HCT15 cells as revealed in CI and DRI values.
Recently, Shi et al (2015) reported that metformin also potentiates the anticancer activity of imatinib in CML cells.
To elucidate the underlying mechanism for the synergism of the imatinib and metformin combination, we explored changes in the levels of pERK1/2. Interestingly, our study showed that metformin alone significantly suppressed pERK level. Metformin is known to inhibit mitochondrial complex I (NADH dehydrogenase) activity in the electron transport chain, which in turn increases the cellular AMP/ ATP ratio. This high AMP/ATP ratio activates the phosphorylation of AMPK, a master energy sensor within cell, and then pAMPK inhibits mTOR signaling by activating TSC2 and subsequently inhibiting Rheb (Quinn et al., 2013; Wheaton et al., 2014) . Therefore we anticipated that metformin might increase pERK, considering that RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways negatively regulates each other's activity and mTOR inhibitorbased therapy often resulted in drug resistance due to the activation of ERK (Mendoza et al., 2011) . Currently, the
reason is yet unclear, but there are some reports showing the decrease of pE.
RK following metformin treatment (Niehr et al., 2011) .
In addition, Alimova et al (2009) suggested that the high concentration of metformin inhibits the epidermal growth factor receptor activity, which leads to reduction of pERK in breast cancer cells. The exact mechanism of anticancer activity of metformin at molecular level is a matter of debate, and there is a conflicting issue on the high doses of metformin (1-20 mM) used in vitro cell culture study compared to serum levels (6-30μM) observed in diabetic patients to whom metformin is prescribed. One possible explanation for this may be that cultured cell lines have not the cationic transporter OCT1 to enter metformin into cytoplasm (Niehr et al., 2011) . Another is the positively charged metformin is accumulated in tissues or within mitochondria. This might reach the local concentration of metformin up to 1,000 fold higher than the serum levels, similar doses to those used in cell culture models (Wilcock & Bailey, 1994) .
Molecular targeted agents for cancer therapeutics are known to induce cell cycle arrest and much attention has been paid to the control of cell cycle in the field of oncology. In our current study, flow cytometry showed that metformin, imatinib and the combination caused an increase in S phase or G 2 /M phase population 24 hr after treatment.
This is in good agreement with the result of western blot analysis showing that cyclin B1 levels were markedly reduced with no apparent changes of cyclin D1 and cyclin A levels after treatments of metformin, imatinib and the combination, since the accumulation of cyclin B1 protein begins at the S phase and reaches the maximal level at G 2 /M phase (Norbury & Nurse, 1992) . In contrast, several studies described that Abl tyrosine kinase regulates cell cycle and blocking of Abl tyrosine kinase with imatinib reduces cell proliferation via depletion of cyclinD1 and hence leads to G 1 arrest of cell cycle (Genander et al., 2009 ). However, a report with CML cells showed that imatinib brings about a transient G 1 phase accumulation and S phase depletion peaking at 12 hr after treatment followed by a progressive decrease of G 1 phase content and accumulation in S phase at 24 hr (Huguet et al., 2008) .
Thus, the discrepancy of our results with others seems to reside in the time-dependent changes in cell cycle distribu- (Crowley et al., 2013) .
Taken together, our study reveals that metformin and imatinib inhibits cell viability in dose-dependent manner and metformin synergistically augments the anticancer activity of imatinib in HCT15 CRC cells. Moreover, we
showed that autophagy is activated in response to metformin, imatinib and the combination, and the blockage of autophagy resulted in the decrease of cell viability. Thus, our findings suggest that metformin may be used clinically to enhance the antitumor effect of imatinib and inhibition of autophagy can be a potential strategy to increase therapeutic efficacy of imatinib in combination with metformin.
Further comprehensive studies are required to examine in vivo synergistic antitumor effect of imatinib and metformin combination therapy for the clinical application.
